Aurobindo Pharma's net profit fell 10% to Rs 846 crore in Q3 FY25, while revenue rose to Rs 7,979 crore. The company attributes this to volume growth and new launches.

Aurobindo Pharma reported a 10% YoY decline in net profit to Rs 846 crore for Q3FY25, mainly due to a decrease in US sales.

Ahead of earnings announcement, shares of Aurobindo Pharma ended the trading session flat at ₹1,184.50 apiece on the BSE, ...

Aurobindo Pharma on Thursday reported a 10 per cent year-on-year (Y-o-Y) drop in consolidated profit after tax (PAT) for the ...

The Hyderabad-based bulk and generic drug maker's net profit fell 9.7% year-on-year to Rs 846 crore in the quarter ended Dec.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

AM(IST)on Friday in an upbeat market. Torrent Pharmaceuticals Ltd.(up 1.67 per cent), Aurobindo Pharma Ltd.(up 1.22 per cent) ...

Indian drugmaker Aurobindo Pharma reported a lower third-quarter profit on Thursday, as a spike in expenses more than offset strong demand for its generic drugs.

The Board of Aurobindo Pharma at its meeting held on 06 February 2025 has approved to enter into a power purchase agreement with Swarnaaskshu Solar Power (Swarnaaskshu), a company under incorporation, ...

Aurobindo Pharma's net profit declines 10% due to lower U.S. formulations revenue, but revenue from operations increases.

The Unit 2, API manufacturing facility is of Apitoria Pharma Pvt Ltd, a wholly-owned subsidiary of the company. It is located ...

As on Feb 06, 2025, Aurobindo Pharma Ltd (AUROPHARMA)’s share price on NSE is Rs 1191.8 What is the market cap of Aurobindo Pharma Ltd (AUROPHARMA?) The current market capitalisation of ...